Although the CD133-targeted CAR-T cell infusion was tolerated in cancer patients, its toxicity leading to a decrease in haemoglobin, lymphocytes and platelets remains a challenge to overcome before repeated and extended infusion is possible. The gene discussed is PROM1; the disease is cancer.